

# Linus Angenendt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8379441/publications.pdf>

Version: 2024-02-01

32  
papers

602  
citations

759055

12  
h-index

642610

23  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. <i>Blood Advances</i> , 2022, 6, 3684-3696.	2.5	5
2	Emerging antibody-based therapies for the treatment of acute myeloid leukemia. <i>Cancer Treatment Reviews</i> , 2022, 108, 102409.	3.4	5
3	Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 494-503.	1.2	12
4	Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 192, e148-e151.	1.2	4
5	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. <i>Blood</i> , 2021, 138, 318-330.	0.6	98
6	Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. <i>European Journal of Cancer</i> , 2021, 150, 143-154.	1.3	9
7	Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML. <i>Blood Advances</i> , 2021, 5, 4413-4421.	2.5	9
8	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. <i>Nature Communications</i> , 2021, 12, 422.	5.8	36
9	Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Annals of Hematology</i> , 2021, 100, 1871-1878.	0.8	3
10	Are formalin-fixed and paraffin-embedded tissues fit for proteomic analysis?. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4347.	0.7	13
11	A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e638.	3.1	5
12	First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. <i>Cancers</i> , 2020, 12, 1488.	1.7	15
13	Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1410-1420.	1.3	7
14	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020, 1, 100158.	3.3	18
15	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	0.8	77
16	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. <i>Nature Communications</i> , 2019, 10, 3475.	5.8	43
17	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2830-2841.	3.3	30
18	Pure red cell aplasia after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1864-1866.	2.6	0

#	ARTICLE	IF	CITATIONS
19	An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 510-519.	3.3	7
20	Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2018, 52, 1701637.	3.1	7
21	Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 517-525.	2.1	8
22	Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. <i>Translational Oncology</i> , 2018, 11, 1271-1282.	1.7	20
23	AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 455-462.	2.1	8
24	RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 243-248.	2.3	13
25	Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 443-445.	1.3	49
26	A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0164499.	1.1	11
27	NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. <i>Oncotarget</i> , 2016, 7, 6774-6789.	0.8	19
28	MN1's Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells. <i>Oncogenesis</i> , 2015, 4, e179-e179.	2.1	11
29	Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Cancer Immunology Research</i> , 2015, 3, 547-556.	1.6	39
30	Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. <i>Leukemia Research</i> , 2015, 39, 739-748.	0.4	14
31	Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease. <i>Annals of Hematology</i> , 2015, 94, 1241-1243.	0.8	7
32	Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 980-980.	0.6	0